Artivion, Inc. (NYSE:AORT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Artivion, Inc. (NYSE:AORT) have earned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $43.9667.

AORT has been the subject of several research reports. JMP Securities lifted their price objective on shares of Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research note on Friday, October 10th. LADENBURG THALM/SH SH downgraded shares of Artivion from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $32.00 to $38.80 in a research note on Wednesday, August 13th. Needham & Company LLC lifted their price objective on shares of Artivion from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, August 22nd. Oppenheimer reiterated an “outperform” rating on shares of Artivion in a research note on Friday, August 8th. Finally, Canaccord Genuity Group lifted their price objective on shares of Artivion from $41.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, September 29th.

Insider Buying and Selling at Artivion

In related news, SVP Marshall S. Stanton sold 18,200 shares of the firm’s stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $44.02, for a total transaction of $801,164.00. Following the completion of the transaction, the senior vice president owned 64,200 shares of the company’s stock, valued at $2,826,084. This trade represents a 22.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John E. Davis sold 10,802 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $43.67, for a total transaction of $471,723.34. Following the transaction, the insider directly owned 208,778 shares of the company’s stock, valued at approximately $9,117,335.26. This trade represents a 4.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 74,858 shares of company stock worth $3,250,129. 8.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Oregon Public Employees Retirement Fund raised its holdings in shares of Artivion by 5.8% during the third quarter. Oregon Public Employees Retirement Fund now owns 9,329 shares of the company’s stock worth $395,000 after purchasing an additional 510 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in Artivion by 1.8% in the third quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock valued at $985,000 after buying an additional 414 shares in the last quarter. SG Americas Securities LLC purchased a new position in Artivion in the third quarter valued at $244,000. KLP Kapitalforvaltning AS increased its holdings in Artivion by 19.1% in the third quarter. KLP Kapitalforvaltning AS now owns 8,100 shares of the company’s stock valued at $343,000 after buying an additional 1,300 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its holdings in Artivion by 6.1% in the third quarter. Louisiana State Employees Retirement System now owns 19,100 shares of the company’s stock valued at $809,000 after buying an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Trading Up 1.2%

NYSE:AORT opened at $45.27 on Wednesday. Artivion has a 12 month low of $21.97 and a 12 month high of $45.79. The firm has a fifty day simple moving average of $42.11 and a 200-day simple moving average of $34.21. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $2.14 billion, a P/E ratio of -107.78 and a beta of 1.67.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.11 by $0.13. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business had revenue of $112.97 million during the quarter, compared to the consensus estimate of $107.96 million. The firm’s revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Artivion will post 0.37 earnings per share for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.